The value of urodynamic tools to guide patient selection in sacral neuromodulation

Jamie Drossaerts · Kevin Rademakers · Gommert van Koeveringe · Philip Van Kerrebroeck

Received: 5 November 2014 / Accepted: 3 January 2015 / Published online: 14 February 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Purpose The aim of this study is to explore whether urodynamics, with the addition of ambulatory urodynamic study (ambulatory-UDS), will be able to better predict and assess sacral neuromodulation (SNM) treatment outcome. Selection of patients is a critical element in achieving optimal outcome in SNM. Quantitative and qualitative results of urodynamic tests are used to justify surgical therapy and to evaluate treatment for lower urinary tract dysfunction. Therefore, these tests should be representative and subsequently offer a correct prognosis.

Methods Between December 2002 until May 2013 selected patients with lower urinary tract symptoms (storage and/or voiding dysfunction) were included in an ambulatory urodynamic measurement database. From this database, the total subgroup of patients that underwent a sacral neuromodulation test evaluation was selected.

Results A total of 98 patients were included. Success rate of SNM in patients with storage dysfunction was around 70%, according to either conventional-UDS or ambulatory-UDS diagnosis. Based on conventional-UDS, success rate of SNM in patients with hypocontractility was 67% and in acontractile patients 35%. According to ambulatory-UDS diagnosis, success rates were 32 and 17%, respectively.

Conclusions This study shows that conventional-UDS overestimates the amount of patients diagnosed with hypocontractile or acontractile bladder. Patients with reduced contractility on ambulatory-UDS have a lower chance of SNM success. Hence, ambulatory-UDS allows us to select patients with a real acontractile bladder and predict SNM failure. In patients with storage dysfunction, additional ambulatory-UDS does not seem to contribute in predicting SNM outcome.

Keywords Sacral neuromodulation · Refractory overactive bladder · Non-obstructive urinary retention · Urodynamics · Conventional urodynamic study · Ambulatory monitoring

Abbreviations

Ambulatory-UDS Ambulatory urodynamic study
Conventional-UDS Conventional urodynamic study
DO Detrusor overactivity
DU Detrusor underactivity
NOR Non-obstructive urinary retention
OAB Overactive bladder
SNM Sacral neuromodulation

Introduction

Since the 1990s, sacral neuromodulation (SNM) is recommended as a secondary treatment option if conservative treatments either fail or lead to adverse events in patients with overactive bladder syndrome (OAB) or non-obstructive urinary retention (NOR). OAB syndrome is defined
by the International Continence Society (ICS) as urgency, frequency and/or nocturia with or without urgency incontinence [1]. NOR has a multifactorial aetiology and can be caused by detrusor underactivity (DU), detrusor-bladder neck dyssynergia, detrusor-external sphincter dys-synergia, dysfunctional voiding and non-relaxing ure-thral sphincter obstruction. Treatment success of these storage and voiding dysfunctions is evaluated in terms of improvement in micturition diaries, subjective patient evaluation, quality of life scores and symptom score questionnaires.

Conventional urodynamic studies (conventional-UDS) use retrograde bladder filling via a catheter to monitor storage and voiding in a patient. Ambulatory urodynamic studies (ambulatory-UDS) aim to evaluate storage and voiding during natural filling of the bladder [2]. Since the development of ambulatory-UDS in the 1990s [2, 3], many studies have been performed to assess the utility of ambulatory-UDS in clinical practice. Ambulatory urodynamic studies were standardised in 2000 [4], but have yet to be clinically validated. It can be expected that the ambulatory-UDS technique is more sensitive in recording pressure/flow changes than conventional urodynamic measurements, which are currently the gold standard in urodynamics. However, ambulatory-UDS may also be more sensitive to artifacts and could be more prone to record or elicit non-physiological detrusor behaviour [5]. Others mention that the rapid filling in conventional-UDS could elicit artifacts and/or mask (other) artifacts that do manifest themselves during ambulatory-UDS [6]. These and other factors make validation a complex task. Nonetheless, it remains a necessary step in the clinical application of ambulatory-UDS. To correctly validate ambulatory-UDS, urodynamic results of conventional-UDS and ambulatory-UDS should be compared with each other on a large scale and both should be related to treatment outcome in different treatment modalities. One of these treatment modalities is SNM. In most studies with SNM treatment, success is defined as a reduction in one or more micturition symptoms of ≥50 %, compared to baseline, determined by comparing voiding diaries. However, also changes in urodynamic parameters during SNM have been reported by several research groups. In patients with NOR treated with SNM, a significant correlation was found between improvement in symptoms and changed conventional-UDS recording [7–9]. Several researchers found a similar significant correlation in OAB patients treated with SNM [10–12].

In this article, outcomes of conventional-UDS and ambulatory-UDS in patients evaluated with SNM are reviewed with a focus on the treatment outcome. The aim of this study is to explore to what extent a urodynamic diagnosis, with the addition of ambulatory-UDS, will be able to predict sacral neuromodulation treatment outcome even before SNM test evaluation is performed.

Patients and methods

Selected patients underwent, besides a conventional-UDS, an additional ambulatory-UDS before starting (if any) treatment. Reasons for ambulatory-UDS were as follows: (1) low-quality conventional-UDS (2) assumed OAB syndrome without detrusor overactivity on conventional-UDS (3) incontinence with unclear primary origin (4) suspected bladder acontractility and (5) enuresis nocturna. All patients in this study underwent conventional and ambulatory urodynamic monitoring before treatment evaluation with sacral neuromodulation between December 2002 and April 2013. Clinical informed consent was obtained from all patients for the additional ambulatory-UDS. All urodynamic measurements were performed with the use of Medical Measurements Systems (MMS B.V., Enschede, The Netherlands) equipment and according to the standardisation report of the ICS [4, 13]. Any phasic contraction during the filling phase with rise and fall in detrusor pressure is diagnostic of detrusor overactivity (DO). The ICS definition does not specify a minimum change in detrusor pressure, although waves of an amplitude <5 cm H2O are difficult to detect. Bladder acontractility was defined as a filling and voiding phase without detrusor pressure rise. Hypocontractility was identified as a low detrusor pressure (<10 cm H2O) during the voiding phase, relative to the degree of obstruction, not resulting in (efficient) micturition. In the case of a conventional-UDS, the hypocontractility definition is elaborated with a peak flow rate (Qmax) of <10 mL/s, voided volume should be >100 mL and residual urine volume >150 mL [14]. For ambulatory-UDS standardised limits have not yet been established. The quality of all ambulatory-UDS recordings was probed, and the full results were interpreted by a staff member specialised in urodynamics and a resident experienced in judging urodynamic measurements. SNM treatment success is defined as a reduction in one or more micturition symptoms of ≥50 %, compared to baseline, determined by comparing voiding diaries.

Statistical analysis

Descriptive and comparative statistics were calculated with the use of SPSS, IBM corporation, version 20. Median and 25–75 percentile interquartile range (IQR) were stated. Nominal association variables and measurement of agreement between conventional-UDS and ambulatory-UDS were calculated. Logistic regression analysis was performed to compare success rate by conventional and ambulatory urodynamic diagnoses.
Results

A total of 98 patients underwent conventional-UDS and ambulatory-UDS before the neuromodulation test. The median age of included patients was 54 years (IQR 45–62), and the group consisted of 67 women and 31 men. Reasons for conducting a conventional-UDS were OAB (n = 25: wet, n = 3; dry), mixed urinary incontinence (n = 11) and voiding problems (n = 59). In 44 patients, the ambulatory-UDS was conducted after an inconclusive or unrepresentative conventional-UDS, in 40 patients because of alleged acontractility or hypocontractility, and in 14 patients because of OAB symptoms without DO on conventional-UDS. The median (IQR) duration of an ambulatory-UDS was 5.5 h (4.1–6.0), with a median drinking volume during the assessment of 1,400 mL (1,025–1,860) and median urine production of 660 mL (265–1,050). In 54 (55 %) patients, the evaluation led to permanent treatment with sacral neuromodulation. Twelve patients experienced faecal incontinence in addition to urgency urinary incontinence. In 67 % of these patients, faecal incontinence symptoms decreased by ≥50 % during SNM.

Conventional-UDS and ambulatory-UDS outcomes compared

Overall there is a high association between conventional-UDS and ambulatory-UDS outcomes (Cramer’s V = 0.336 (p < 0.001), Pearson’s contingency coefficient: C = 0.558 (p < 0.001)) see Table 1, subset A. Success rates based on conventional-UDS are not significantly (V = 0.272 (p = 0.124), C = 0.262 (p = 0.124)) different from the success of patients with normal conventional-UDS recordings, no matter what the specific diagnosis, as can be seen in Fig. 1. The association between outcomes of conventional-UDS and successful SNM treatment is also not significant when stratified for patients based on history of storage or voiding dysfunction. This is in contrast to the relationship between outcomes of ambulatory-UDS and successful SNM treatment, as there is a moderate association [V = 0.435 (p = 0.001), C = 0.399 (p = 0.001)], between them.

Storage dysfunction

SNM treatment success rates were around 70 % in patients with a diagnosis of OAB after history taking and performance of urodynamics (Fig. 1). The total group was also stratified purely on history taking between (mainly) storage or voiding dysfunction. Of the 39 patients with a history of storage dysfunction, only 11 showed signs of OAB on conventional-UDS. On the other hand, 26 showed indications of OAB on ambulatory-UDS. Of these 39, only seven patients (18 %) showed DO on conventional urodynamics. On ambulatory-UDS of the same patients, 32 (82 %) showed contractions during the filling phase. These 32 patients included the seven patients with DO on conventional-UDS. If storage dysfunction was confirmed on both urodynamic tests, success rate was almost 40 % higher (Table 1, subset B) than when only seen on one of both tests (success rates were on average 79 %). If storage dysfunction was only seen on one of the two, success rate on average was 57 %, regardless of the urodynamic test. The presence or absence of DO or ‘detrusor contractions during the filling phase’ in addition to the storage symptoms did not change this similarity in success rate for both conventional-UDS and ambulatory-UDS. This is in concordance with the finding that when SNM is successful in patients with a history of storage dysfunction, there is a significant association between the conventional-UDS-based and the ambulatory-UDS-based diagnoses (C = 0.767, p < 0.001).

Voiding dysfunction

Of the group of patients with a history of voiding dysfunction, 53 % (31 of 59) had a successful SNM evaluation period (Table 1, subset C). Of these 59 patients with a history of bladder emptying problems, 23 (39 %) were acontractile on conventional-UDS. On ambulatory-UDS, only 6 (10 %) of the 59 appeared to be acontractile. Hence, in 78 % of patients (18/23), the diagnosis of acontractility on conventional-UDS was not confirmed on ambulatory-UDS. All five patients with acontractility on both conventional-UDS and ambulatory-UDS failed the SNM test period. Eight (35 %) of these 23 patients showed hypocontractility on ambulatory-UDS, and 63 % of these patients underwent successful SNM test period. Additionally, nine patients showed hypocontractility on conventional-UDS, of which four were also hypocontractile on ambulatory-UDS. If hypocontractility was confirmed by ambulatory-UDS, failure rate was 40 % higher than when diagnosis was only based on conventional-UDS. Finally, three patients with a history of storage dysfunction appeared to be acontractile on conventional-UDS, and none of these patients were acontractile on ambulatory-UDS. These patients also had a successful neuromodulation test.

Long-term response

Of all 98 patients evaluated, 54 (55 %) underwent permanent implantation as a result of significant reduction in symptoms during the test stimulation. After 1 year, 98 % still were successfully treated (without a decline of the initial improvement), after 2 years this percentage dropped to 94 %, as is shown in Fig. 1. Several patients (n = 19) are treated with SNM for a period longer than 5 years, and
in this group most patients (89%) still have a favourable effect of the treatment. In case patients show an effect during initial SNM evaluation, there is no significant difference (p > 0.05) between the different SNM indications with regard to long-term effect.

### Discussion

In the past, it has been attempted to identify which patients are more likely to benefit from treatment with SNM. It appears to be difficult to define reliable predictive factors [15, 16]. It is assumed that patients with a real acontractile bladder have a lower SNM treatment success rate [8]. However, how to determine this real acontractile bladder remained unclear [17]. Some also assumed that OAB patients with DO on urodynamics could have a higher potential treatment success, compared to the OAB patients without DO [15].

This study is relating urodynamic recordings, taking symptom presentation into account, to treatment outcome in SNM and could be a first step towards validation of the ambulatory-UDS. It provides clues that performing ambulatory urodynamics in selected patients will lead to a better patient selection and thus more successful SNM outcomes. In this study treatment, success rate amongst patients with storage dysfunction (around 70%) was higher than in the patients with voiding dysfunction (around 50%).
lowest success rate was seen in the patients with hypoco-
trictility or acontractility on ambulatory-UDS (re-
spectively, 32 and 17 %). In 78 %, the diagnosis of acon-
tractility on conventional-UDS was not confirmed with
ambulatory-UDS.

Although ambulatory-UDS is not validated yet, the
recording of a detrusor contraction can easily be detected.
An acontractile bladder confirmed on ambulatory-UDS is
therefore definitely more reliable to be a real acontractile
bladder.

Filling phase contractions were more abundant on ambu-
latory-UDS recordings than on conventional-UDS in this
study. Both on conventional-UDS and on ambulatory-UDS,
the presence of OAB with DO or filling phase contrac-
tions did not lead to a difference in outcome, compared to
patients with OAB without these contractions. In another
study, OAB patients were treated with Onabotulinumtox-
inA bladder injections, and treatment outcome does not
appear to be related to the pretreatment urodynamic finding
of DO neither [18].

In general not only in symptomatic patients [6], but also
in asymptomatic individuals, an increase in the number of
detrusor contractions during the storage phase on ambu-
latory-UDS has been found [2, 19, 20]. It has been noted
that about 50 % of patients are continuously aware of the
catheter and have increased urge sensation, but they volun-
tarily suppress their reaction [2]. Detrusor overactivity has
also been found on ambulatory-UDS in patients with only
stress urinary incontinence symptoms [21, 22]. The signif-
icance of detrusor contractions without subsequent leak-
age in asymptomatic patients is unknown. The increased
number of contractions can be elicited by catheter irrita-
tion or due to artifacts. It cannot be excluded nor proven
that the bladder catheter is a non-physiological trigger
and may explain the high incidence of detrusor over-
activity [23]. The meaning of this higher false-negative
rate in diagnosing DO on conventional-UDS compared
to ambulatory-UDS has yet to be elucidated [24]. DO
seen on ambulatory-UDS may have other diagnostic and
therapeutic consequences than DO seen on conventional-
UDS. Therefore, the meaning of DO on ambulatory-UDS
needs further explanation. However, these findings will not
change the conclusions based on our results, as was shown
that the detection of DO does not predict a different SNM
treatment outcome.

The patients included in this study are a clinically pre-
selected group with more complex pathology, compared to
other patients that did not undergo additional ambulatory-
UDS. This can also explain the lower average success rate
of SNM evaluation (54 %), as this is around 70 % in the
total treatment group in our tertiary referral population.
This patient selection raises a risk of bias, as ambulatory
urodynamics is performed on specific indication, rather
than randomly.
Another point of discussion is the representativeness of the diagnosis in repeated urodynamic studies. Regardless of the urodynamic study being ambulatory or conventional, the fact of having multiple urodynamic studies could lead to a higher recording rate of symptom related events. As most patients already underwent repeated conventional-UDS before additional ambulatory-UDS, the influence of this possible source of bias seems negligible.

Ambulatory urodynamic studies are more time-consuming than conventional-UDS. It remains debatable when they can be of additional value in clinical diagnosis and treatment evaluation. This additional evaluation should be reserved for patients in which conventional pressure flow studies have failed to fully explain or reproduce the symptoms and where further knowledge is likely to aid in subsequent management. Based on results from this study, we advise to perform ambulatory-UDS in patients with alleged diminished bladder contractility. The value of contractions during the filling phase with ambulatory-UDS in patients with OAB complaints, without DO on conventional-UDS, should be the subject of future research. Future studies should also define normal ranges for filling and voiding cystometry in ambulatory-UDS. This, in combination with the process of relating urodynamic results to treatment outcomes in patients with lower urinary tract symptoms, will be useful in the clinical validation of ambulatory-UDS.

Conclusions

In patients with storage dysfunction, regardless of the presence of detrusor overactivity, additional ambulatory-UDS does not seem to contribute to a better prediction of success with SNM. However, it could be of importance in other treatments. Ambulatory-UDS is more sensitive in detecting detrusor contractions in patients with voiding dysfunction. The success rate amongst the patients with hypocontractility or acontractility is higher based on conventional-UDS than on ambulatory-UDS. The most likely cause of this discrepancy is the overestimation of the amount of patients with impaired contractility when relying on conventional-UDS. The diagnosis of a real acontractile bladder implicates an obvious high risk of failure of SNM. This information makes more accurate patient selection for SNM possible.

Therefore, ambulatory urodynamics could better guide treatment choice than conventional-UDS in these patients.

Acknowledgments The personnel of the Department of Urology of the Maastricht UMC+ are gratefully acknowledged. Especially M.S. Rahnama’i (M.D. Ph. D.) and T. Marcelissen (M.D. Ph. D.) contributed to the setup of the ambulatory-UDS database.

Conflict of interest J. Drossaerts reports grants from Medtronic, outside the submitted work. K. Rademakers has nothing to disclose regarding the submitted work. G. van Koeveringe has nothing to disclose regarding the submitted work. Ph. Van Kerrebroeck reports grants from Medtronic, personal fees from Medtronic, outside the submitted work.

Ethical standard This study does not contain clinical interventional study data to which the ethical standard statement apply.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49
2. van Waalwijk DES, Remmers A, Janknegt RA (1991) Extra-mural ambulatory urodynamic monitoring during natural filling and normal daily activities: evaluation of 100 patients. J Urol 146(1):124–131
3. Comarr AE (1957) Excretory cystometry: a more physiologic method. J Urol 77(4):622–633
4. van Waalwijk DE, Anders K, Khullar V, Kulseng-Hanssen S, Pesce F, Robertson A, Rosario D, Schafer W (2000) Standardisation of ambulatory urodynamic monitoring: report of the Standardisation Sub-Committee of the International Continence Society for Ambulatory Urodynamic Studies. Neurolour Urodyn 19(2):113–125
5. Brown K, Hilton P (1997) Ambulatory monitoring. Int Urogynecol J 8(6):369–376
6. van Koeveringe GA, Rahnama’i MS, Berghmans BC (2010) The additional value of ambulatory urodynamic measurements compared with conventional urodynamic measurements. BJU Int 105(4):508–513. doi:10.1111/j.1464-410X.2009.08790.x
7. Jonas U, Fowler CJ, Chancellor MB, Elhilali MM, Fall M, Gajewski JB, Grunewald V, Hassouna MM, Hombergh U, Janknegt R, van Kerrebroeck PE, Lycklama a Nijeholt AA, Siegel SW, Schmidt RA (2001) Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 165(1):15–19
8. Everaert K, Plancke H, Lefevere F, Oosterlinck W (1997) The urodynamic evaluation of neuromodulation in patients with voiding dysfunction. Br J Urol 79(5):702–707
9. DasGupta R, Fowler CJ (2004) Urodynamic study of women in urinary retention treated with sacral neuromodulation. J Urol 171(3):1161–1164. doi:10.1097/01.ju.0000132012.26176.8f
10. Weil EH, Ruiz-Cerda JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE (2000) Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol 37(2):161–171. doi:10.1159/000020134
11. Hassouna MM, Siegel SW, Nyeholt AA, Elhilali MM, van Kerrebroeck PE, Das AK, Gajewski JB, Janknegt RA, Rivas DA, Dijkema H, Milam DF, Oleson KA, Schmidt RA (2000) Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 163(6):1849–1854
12. Scheepens WA, van Koeveringe GA, de Bie RA, Weil EH, van Kerrebroeck PE (2003) Urodynamic results of sacral
neuromodulation correlate with subjective improvement in patients with an overactive bladder. Eur Urol 43(3):282–287

13. Rowan D, James ED, Kramer AE, Sterling AM, Suhel PF (1987) Urodynamic equipment: technical aspects. Produced by the International Continence Society Working Party on Urodynamic Equipment. J Med Eng Technol 11(2):57–64

14. Abarbanel J, Marcus EL (2007) Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology 69(3):436–440. doi:10.1016/j.urology.2006.11.019

15. Koldewijn EL, Rosier PF, Meuleman EJ, Koster AM, Debruyne FM, van Kerrebroeck PE (1994) Predictors of success with neuromodulation in lower urinary tract dysfunction: results of trial stimulation in 100 patients. J Urol 152(6 Pt 1):2071–2075

16. Scheepens WA, Jongen MM, Nieman FH, de Bie RA, Weil EH, van Kerrebroeck PE (2002) Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction. Urology 60(4):598–602

17. Bertapelle P, Bodo G, Carone R (2008) Detrusor acontractility in urinary retention: detrusor contractility test as exclusion criteria for sacral neurostimulation. J Urol 180(1):215–216. doi:10.1016/j.juro.2008.03.054

18. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30(4):556–562. doi:10.1002/nau.21021

19. Heslington K, Hilton P (1996) Ambulatory monitoring and conventional cystometry in asymptomatic female volunteers. Br J Obstet Gynaecol 103(5):434–441

20. Schmidt F, Jorgensen TM, Djurhuus JC (2004) Twenty-four-hour ambulatory urodynamics in healthy young men. Scand J Urol Nephrol Suppl 215:75–83. doi:10.1080/03008880410015327

21. Digesu GA, Hendricken C, Fernando R, Khullar V (2009) Do women with pure stress urinary incontinence need urodynamics? Urology 74(2):278–281. doi:10.1016/j.urology.2009.01.089

22. Swithinbank LV, James M, Shepherd A, Abrams P (1999) Role of ambulatory urodynamic monitoring in clinical urological practice. Neurourol Urodyn 18(3):215–222

23. Sand PK, Hill RC, Ostergard DR (1988) Incontinence history as a predictor of detrusor stability. Obstet Gynecol 71(2):257–260

24. Dokmeci F, Seval M, Gok H (2010) Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence. Neurourol Urodyn 29(4):518–521. doi:10.1002/nau.20821